1 Department of Inflammation Biology, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom.
2 Department of Renal Medicine, King’s College Hospital NHS Foundation Trust, London, United Kingdom.
3 Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London, United Kingdom.
4 Department of Haematology, Kings College Hospital NHS Foundation Trust, London, United Kingdom.
Received 3 April 2022. Revision received 21 June 2022.
Accepted 26 June 2022.
C.C.S. has received honoraria from Novartis Pharmaceuticals, Travere Pharmaceuticals, and Vifor Pharmaceuticals for consultancy work. The other authors declare no conflicts of interest.
C.C.S., A.S., and S.S.-S. all contributed to the writing and review of this article.
Correspondence: Claire C. Sharpe, MBBS, PhD, Renal Sciences, James Black Centre, 10 Cutcombe Rd, King’s College London, London SE5 9RJ, United Kingdom. ([email protected]).